27 related articles for article (PubMed ID: 38437792)
1. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
3. The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience.
Shah S; Shaing C; Khatib J; Lodrigues W; Dreadin-Pulliam J; Anderson BB; Unni N; Farr D; Li HC; Sadeghi N; Syed S
Clin Breast Cancer; 2022 Dec; 22(8):823-827. PubMed ID: 36089460
[TBL] [Abstract][Full Text] [Related]
4. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
Foldi J; Tsagianni A; Salganik M; Schnabel CA; Brufsky A; van Londen GJ; Pusztai L; Sanft T
BMC Cancer; 2023 Jun; 23(1):606. PubMed ID: 37391697
[TBL] [Abstract][Full Text] [Related]
5. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Sanft TB; Wong J; O'Neal B; Siuliukina N; Jankowitz RC; Pegram MD; Fox JR; Zhang Y; Treuner K; O'Shaughnessy JA
J Natl Compr Canc Netw; 2024 Mar; 22(2):99-107. PubMed ID: 38437792
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine in extended adjuvant endocrine therapy for breast cancer.
Tesch ME
Curr Opin Oncol; 2023 Nov; 35(6):453-460. PubMed ID: 37621168
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX; Bose R; Ellis MJ
Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
[TBL] [Abstract][Full Text] [Related]
11. Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer.
Anandan A; Sharifi M; O'Regan R
Curr Treat Options Oncol; 2020 Aug; 21(10):84. PubMed ID: 32803324
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
